|
|
 Previous Article | Table of Contents | Next Article 
Retinoic Acid Induces Aggregation of the Acute Promyelocytic Leukemia Cell Line NB-4 by Utilization of LFA-1 and ICAM-2
Richard S. Larson,
David C. Brown, and
Larry A. Sklar
From the Department of Pathology, University of New Mexico Cancer Center, Albuquerque, NM.
All-trans retinoic acid (tRA) is a potent differentiation agent that is effective therapy for acute promyelocytic leukemia (APL). However, 5% to 25% of patients develop retinoic acid syndrome, a potentially life-threatening complication in which the pathogenesis relates to adhesive alterations of APL cells. Therefore, we investigated the relationship between tRA-induced differentiation and the adhesive properties of APL cells. After confirming differentiation-related morphological changes of NB-4 cells in response to tRA, we showed that homotypic aggregation of NB-4 cells grown in tRA for 72 hours is dose-dependent with a median effective dose of approximately 50 nmol/L. Maximal aggregation occurred at mean and peak therapeutic serum concentrations (100 and 1,000 nmol/L, respectively). Aggregation also increased with the length of tRA exposure over 168 hours. Aggregation was inhibited by neutralizing antibodies against LFA-1 and ICAM-2. Notably, antibodies directed against VLA-4, other  2 integrins (Mac-1 and p150), or other potential LFA-1 counterstructures that were expressed on the cell surface (ICAM-1 and ICAM-3) did not block aggregation. Aggregation occurred with similar kinetics regardless of the presence of phorbol ester or the "activating" monoclonal antibody (MoAb) KIM 185, suggesting that the avidity of LFA-1 is not modulated on NB-4 cells in a manner similar to other leukocytes. Consistent with the prompt clinical effectiveness of methyl prednisolone sodium succinate (MPSS) in retinoic acid syndrome, MPSS rapidly inhibited homotypic aggregation in a dose-dependent manner. Thus, tRA alters the adhesive properties of APL cells by inducing the expression of high-avidity 2 integrins, aggregation is inhibited by LFA-1 and ICAM-2 MoAb, and tRA effects are rapidly reversible by MPSS. Taken together, our findings provide a clinically relevant system for study of LFA-1/ICAM-2 interaction and suggest a mechanism in part for retinoic acid syndrome and the effectiveness of MPSS in ameliorating retinoic acid syndrome.
Blood, Vol. 90 No. 7 (October 1), 1997:
pp. 2747-2756
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Cunha De Santis, M. de Barros Tamarozzi, R. B. Sousa, S. E. Moreno, D. Secco, A. B. Garcia, A. S. G. Lima, L. H. Faccioli, R. P. Falcao, F. Q. Cunha, et al.
Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia
Haematologica,
December 1, 2007;
92(12):
1615 - 1622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Dore, B. A. A. Santana-Lemos, V. M. Coser, F. L. S. Santos, L. F. Dalmazzo, A. S. G. Lima, R. H. Jacomo, J. Elias Jr, R. P. Falcao, W. V. Pereira, et al.
The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia
J. Leukoc. Biol.,
November 1, 2007;
82(5):
1340 - 1343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.Y. Au, P. Lam, and T.W. Shek
Uncommon Presentations of Some Common Malignancies: CASE 2. Nasopharyngeal Carcinoma Followed by Secondary Acute Promyelocytic Leukemia Presenting With Respiratory Distress
J. Clin. Oncol.,
February 20, 2005;
23(6):
1314 - 1315.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Battistella, L. D Burry, and J. T Seki
Retinoic acid syndrome after one dose of all-transretinoic acid
Journal of Oncology Pharmacy Practice,
September 1, 2004;
10(3):
149 - 154.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. J. Chung, S.-G. Hwang, P. Nguyen, S. Lee, J.-S. Kim, J. W. Kim, P. A. Henkart, D. P. Bottaro, L. Soon, P. Bonvini, et al.
Regulation of leukemic cell adhesion, proliferation, and survival by beta -catenin
Blood,
July 18, 2002;
100(3):
982 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Jung, J. E. Choi, S. T. Hahn, C. K. Min, C. C. Kim, and S. H. Park
Radiologic Features of All-Trans-Retinoic Acid Syndrome
Am. J. Roentgenol.,
February 1, 2002;
178(2):
475 - 480.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Babina, K. Mammeri, and B. M. Henz
Retinoic acid up-regulates myeloid ICAM-3 expression and function in a cell-specific fashion--evidence for retinoid signaling pathways in the mast cell lineage
J. Leukoc. Biol.,
March 1, 2001;
69(3):
361 - 372.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Ferrara, F. Morabito, B. Martino, G. Specchia, V. Liso, F. Nobile, P. Boccuni, R. Di Noto, F. Pane, M. Annunziata, et al.
CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy
J. Clin. Oncol.,
March 13, 2000;
18(6):
1295 - 1300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, J. W. Andersen, C. A. Schiffer, F. R. Appelbaum, J. H. Feusner, A. Ogden, L. Shepherd, J. M. Rowe, C. Francois, R. S. Larson, et al.
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
Blood,
January 1, 2000;
95(1):
90 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. De Botton, H. Dombret, M. Sanz, J. S. Miguel, D. Caillot, R. Zittoun, M. Gardembas, A. Stamatoulas, E. Conde, A. Guerci, et al.
Incidence, Clinical Features, and Outcome of All Trans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia
Blood,
October 15, 1998;
92(8):
2712 - 2718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
